NeuroSense Therapeutics (NRSN) investor relations material

Corporate highlights and leadership

• Achieved significant positive results in a placebo-controlled Phase 2b ALS study, with PrimeC slowing disease progression by 33% over 18 months (p=0.007).

• Patent protection for PrimeC extends until 2042, covering formulation, method, and combination.

• Expedited regulatory pathway with orphan drug designation and 505(b)2 status.

• Leadership team and scientific advisory board include experienced executives and renowned neurology experts from leading institutions.

Disease focus and market opportunity

• ALS is a rapidly progressing, terminal disease with an average survival of 2–5 years and limited treatment options.

• Over 200,000 ALS patients worldwide, with more than 30,000 in both the US/Canada and Europe.

• PrimeC targets a market of over 80,000 ALS patients, with an annual market opportunity exceeding $1B and projected 24% patient growth by 2040 in the US and EU.

PrimeC mechanism and clinical results

• PrimeC is a novel, extended-release formulation of two approved drugs, targeting neuroinflammation, iron metabolism, and miRNA dysregulation in ALS.

• Demonstrated safety and tolerability throughout the 18-month PARADIGM Phase 2b trial, with most adverse events mild to moderate.

• Slowed disease progression by 29.2% after 6 months and 32.8% after 18 months (p=0.007), with better outcomes for early treatment.

• 58% improvement in survival rates after 18 months and significant reduction in complications, hospitalization, and respiratory support needs.